Farallon Capital Management

Renew Exim DMCC is owned by Valiant Investment DMCC.

Pentera is a leading provider of automated security validation solutions, designed to help organizations assess the integrity of their cybersecurity measures across their entire attack surface. The company's platform enables continuous testing of security systems, identifying vulnerabilities in real-time and at any scale. By evaluating the threat level of an organization’s network on a daily basis, Pentera focuses on various aspects, including infrastructure, network, and human factors. This proactive approach allows businesses to implement timely remediation strategies, effectively closing security gaps before they can be exploited. Trusted by thousands of security professionals and service providers globally, Pentera plays a crucial role in enhancing cybersecurity resilience.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Canfor is one of the largest producers of sustainable lumber, pulp, and paper globally. Established in 1938 by John Prentice and L.L.G. Bentley in Vancouver, the company began as a small veneer plant and has since evolved into a respected leader in the forest products industry, employing over 5,000 people. Canfor operates primarily in North America and Europe, with lumber mills located in British Columbia, Alberta, the Southeastern United States, and Sweden. The company has two main segments: lumber, which encompasses sawmilling and remanufacturing operations, and pulp and paper, which includes kraft pulp, kraft paper, and bleached chemi-thermomechanical pulp. Canfor is recognized for its commitment to quality products, reliable supply, and exceptional customer service, while also focusing on sustainable, renewable resources to meet the growing global demand.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, dedicated to developing therapeutic antibodies for inflammation and immuno-oncology. The company employs its proprietary somatic hypermutation platform to discover and optimize antibodies that target various diseases. Among its notable product candidates are Etokimab, an anti-IL-33 treatment aimed at conditions such as atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor for generalized pustular psoriasis. AnaptysBio is also advancing a range of immuno-oncology products, including checkpoint modulators and bispecific antibodies, to address cancer treatment needs. The company collaborates with notable partners like TESARO, Celgene Corporation, and GlaxoSmithKline to enhance its research and development efforts. Founded in 2005, AnaptysBio aims to fulfill unmet medical needs through innovative antibody therapies.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Atlas Capital Group, LLC is a real estate investment, development, and management firm founded in 2006 by Jeffrey A. Goldberger and Andrew B. Cohen. The company focuses on opportunistic and value-added real estate projects primarily in key gateway cities, notably New York and Los Angeles. Atlas Capital boasts a vertically integrated team of over 100 specialists who possess expertise across various real estate disciplines, including construction, leasing, development, asset management, property management, accounting, and legal services. This comprehensive approach enables Atlas Capital to effectively navigate the complexities of the real estate market and deliver value to its stakeholders.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). By leveraging advanced antibody engineering, rational therapeutic combinations, and precision medicine strategies for patient selection, Spyre Therapeutics seeks to create next-generation products that address the chronic inflammation associated with IBD, which includes ulcerative colitis and Crohn's disease. The company aims to enhance existing treatment options, which currently include anti-inflammatory drugs, immunosuppressants, and biologics, thereby improving outcomes for patients suffering from these debilitating gastrointestinal disorders.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing innovative therapies for autoimmune diseases and inflammatory disorders. Incorporated in 2018, Ventyx focuses on creating selective inhibitors targeting TYK2, a key mediator in various inflammatory conditions. The company's clinical pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, which aims to provide a safer alternative by avoiding the toxicities linked to broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator intended for ulcerative colitis treatment, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which plays a significant role in multiple inflammatory diseases.

Avidity Biosciences, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of oligonucleotide-based therapies, particularly through its innovative Antibody Oligonucleotide Conjugates (AOC) platform. This technology aims to address the limitations of traditional oligonucleotide therapies by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide treatments. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disease. In addition to this, the company is advancing multiple programs focused on muscle-related conditions, including muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Furthermore, Avidity is expanding its research to include immune and other cell types, positioning itself at the forefront of biopharmaceutical innovation for serious diseases.

HiBob Inc. is a developer of a cloud-based human resources management system designed to modernize HR technology for contemporary workplaces. Founded in 2015 and headquartered in Tel Aviv, Israel, with additional offices in New York and London, HiBob offers its flagship product, Bob, which serves as an integrated human resource information system. This platform facilitates various HR functions, including attendance tracking, time-off management, employee records, compensation management, and performance evaluation. With an intuitive, data-driven design, Bob is tailored for the needs of globally distributed and collaborative work environments. Since its launch, HiBob has experienced significant growth and has become the preferred HRIS for over 1,000 midsize and multinational companies, helping them enhance employee engagement and retention through effective talent management.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.

Auna is a healthcare provider that operates hospitals and clinics in Mexico, Peru, and Colombia. The company offers a range of health care and wellness services, including prepaid healthcare plans in Peru, as well as dental and vision plans in Mexico. Auna's extensive network encompasses various facilities, such as hospitals, outpatient centers, and wellness facilities. It operates through several segments, including Oncosalud Peru, and provides healthcare services in both Colombia and Mexico, with a significant portion of its revenue generated from operations in Peru.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

GreenYellow is a company that specializes in generating electricity through centralized power plants and decentralized photovoltaic projects. It offers solar panels and provides energy supply services to a diverse range of clients, including food and non-food retailers, government agencies, public utilities, and energy providers. The company's focus on energy efficiency includes operating energy efficiency contracts and offering monitoring services that help clients reduce their energy costs. By promoting solar photovoltaics and energy optimization, GreenYellow enables its customers to produce and manage clean energy, thereby creating value and providing a more affordable alternative to conventional energy sources.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Ada Health is a global health company established in 2011 and headquartered in Berlin, Germany. Founded by a team of doctors, scientists, and industry pioneers, Ada Health aims to enhance personal health management through its innovative platform that integrates medical knowledge with intelligent technology. The platform empowers users by providing personalized assessments of their symptoms based on targeted questions about their health. Additionally, it facilitates online video consultations, disease monitoring, and prevention strategies, allowing healthcare professionals to maintain a comprehensive overview of their patients' health situations. Ada Health collaborates with prominent health systems and global non-profit organizations to realize its vision of improving health outcomes for individuals and enhancing the effectiveness of medical care.

Better Therapeutics is a prescription digital therapeutics company focused on discovering, developing, and commercializing software-based solutions for cardiovascular and metabolic diseases. The company employs clinically-validated, FDA-regulated software to provide digital behavioral therapy aimed at altering the behaviors that contribute to these diseases. This approach is designed to enhance patients' quality of life, reduce reliance on medications, and lower healthcare costs. Better Therapeutics integrates neuroscience, lifestyle medicine, and explainable artificial intelligence into a mobile medical app that is prescribed by physicians. This app utilizes patient-generated data to guide clinical decision-making and improve treatment outcomes. Currently, the company's product pipeline includes therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

HiBob Inc. is a developer of a cloud-based human resources management system designed to modernize HR technology for contemporary workplaces. Founded in 2015 and headquartered in Tel Aviv, Israel, with additional offices in New York and London, HiBob offers its flagship product, Bob, which serves as an integrated human resource information system. This platform facilitates various HR functions, including attendance tracking, time-off management, employee records, compensation management, and performance evaluation. With an intuitive, data-driven design, Bob is tailored for the needs of globally distributed and collaborative work environments. Since its launch, HiBob has experienced significant growth and has become the preferred HRIS for over 1,000 midsize and multinational companies, helping them enhance employee engagement and retention through effective talent management.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Zepz is an online money transfer service that enables individuals to send money to friends and family living abroad through computers, smartphones, or tablets. It provides a convenient and cost-effective alternative to traditional money transfer companies, which often charge high fees. Zepz allows users to send funds to over 140 destinations worldwide, including Europe, Asia, Africa, Australia, and the Americas. Recipients can receive money as bank deposits, cash pickups, Mobile Money, or mobile airtime top-ups. The platform is designed to facilitate secure international transfers, utilizing technology that allows customers to manage their funds efficiently, with lower processing fees compared to conventional methods. Zepz operates in 50 countries, aiming to simplify the process of remittance for its users.

Zentera Therapeutics is a biopharmaceutical company.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, that specializes in restoring protein homeostasis through innovative small molecule therapies. The company develops Protein Homeostatic Modulators, including a small molecular glue that targets cereblon for protein degradation, with applications in oncology, inflammation, and other diseases. BioTheryX employs its proprietary PRODEGY platform, which utilizes a library of cereblon binders to design targeted protein degraders (TPDs). Among its key products is BTX-A51, an oral multi-kinase inhibitor aimed at treating specific leukemic stem cell targets and preventing the transcription of oncogenic genes. Founded in 2007, BioTheryX aims to address unmet medical needs by leveraging its expertise in targeted protein degradation.

NeoGenomics Laboratories operates a network of cancer-focused testing facilities in the United States, Switzerland, and Singapore. The company is divided into two main segments: Clinical Services and Pharma Services. It provides a range of genetic and molecular testing services, including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing, aimed at helping clinicians and researchers understand cancer at a genetic level. Additionally, NeoGenomics offers morphologic analysis for diagnosis and supports pharmaceutical companies in their oncology programs through testing services that facilitate drug development and clinical trials. The company's collaboration with Inivata Limited for the commercialization of the InVisionFirst-Lung liquid biopsy test exemplifies its commitment to advancing cancer diagnostics. Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics serves hospitals, pathologists, oncologists, academic centers, and other clinical laboratories, enhancing cancer care through innovative testing solutions.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

LUMICKS specializes in advanced technologies for studying biology and cancer at the single-molecule and single-cell levels. The company aims to bridge the gap between molecular structure and function, enabling researchers to gain insights into complex biological processes. LUMICKS' flagship products, the C-Trap Optical Tweezers and Fluorescence Microscopy, allow for real-time analysis of molecular interactions. Additionally, the z-Movi Cell Avidity Analyzer provides tools for measuring and selecting immune cells based on their interactions with target cells. By facilitating live measurement and imaging, LUMICKS' instruments support researchers in understanding the fundamental causes of diseases, including cancer, and contribute to drug optimization efforts.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

DarioHealth, established in 2011 and headquartered in Caesarea, Israel, is a digital health company specializing in the development and commercialization of patented technologies for mobile, real-time health monitoring. Its flagship product, Dario, is a comprehensive diabetes management solution comprising a pocket-sized blood glucose monitoring device and a multi-featured software application. DarioHealth markets its products directly to consumers and through retail channels, generating revenue primarily from the sale of its smart meters and related disposable test strips and lancets. The company's digital platform, DarioEngage, engages users, provides coaching and support, and offers real-time alerts and trend analysis for chronic illness management. DarioHealth operates internationally, with a presence in the United States, Europe, Australia, and Canada.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing innovative medicines for various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. Founded in 1997, the company focuses on pharmacology and pharmacokinetics, advancing several investigational drugs through clinical trials. Notable candidates include Etrasimod, which is in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn’s disease, and Olorinab, currently in Phase IIb trials for abdominal pain linked to irritable bowel syndrome. Additionally, Arena is developing ralinepag for pulmonary arterial hypertension and APD418 for acute heart failure. The company has formed collaborations with several organizations, including United Therapeutics and Eisai, to enhance its research and expand its market presence. Arena Pharmaceuticals also has a marketed product, lorcaserin, approved for weight management, further demonstrating its commitment to addressing critical health challenges through innovative therapies.

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Kesoram Industries Limited is a diversified manufacturing company based in Kolkata, India, established in 1919. Originally founded as Kesoram Cotton Mills Ltd., the company transitioned into producing rayon in 1959 and subsequently expanded into cement and tire manufacturing. Kesoram Industries markets its cement products under the Birla Shakti brand and offers a range of rayon, transparent paper, and filament yarn products under the Kesoram Rayon brand. The cement segment constitutes a significant portion of its revenue, primarily generated within the Indian market. In 1986, the company adopted its current name to better reflect its broadening portfolio and operations, which have continued to evolve over the decades.

AUTO1 Group GmbH is a Berlin-based technology platform that specializes in the buying and selling of used cars. Founded in 2012, the company connects individual customers and professional car dealers through its digital marketplace, facilitating seamless transactions without the need for negotiation. AUTO1 Group sources used vehicles from various channels, including original equipment manufacturers and dealerships, and offers a certified and diverse inventory through its brands, such as AUTO1.com and Autohero.com. Operating in nearly 30 countries across Europe and North America, Auto1 Group serves both the retail market for private customers and the merchant segment for commercial car dealers. Its services include auction fees and logistics, ensuring a streamlined and transparent process in the used car trade.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. Utilizing its proprietary platform, the company identifies genomic sequences that regulate gene expression, facilitating advancements in viral gene therapy. Encoded Therapeutics has a diverse therapy pipeline targeting various genetic and acquired disorders across multiple disease pathways, including neurocircuitry, metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, the company is dedicated to improving patient outcomes through innovative gene therapy solutions.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Atento is the largest provider of customer relationship management (CRM) and business process outsourcing (BPO) services in Latin America. The company offers a comprehensive range of services, including customer care, sales, collections, back office, and technical support, catering to various sectors such as telecommunications, banking, financial services, healthcare, retail, and public administration. Atento serves its clients through multiple channels, including digital platforms like SMS, email, chat, social media, and applications, as well as traditional voice and in-person interactions. The company operates across several geographical regions, including Brazil, the Americas, and EMEA (Europe, the Middle East, and Africa).

CargoX is a technology-driven freight marketplace based in Sao Paulo, Brazil, established in 2013. The platform connects shipping companies with a network of over 1.4 million trucks, effectively addressing the issue of excess capacity in the transportation sector. By providing real-time information on available truck capacity, CargoX enhances freight visibility and helps shippers identify optimal solutions for transporting a wide range of products throughout Brazil. This approach not only reduces shipping costs for clients but also increases earnings for truck drivers while minimizing CO2 emissions associated with empty trucks on the road.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Generation Bio Co. is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies aimed at treating both rare and prevalent diseases. Founded in 2016 and formerly known as Torus Therapeutics, the company focuses on creating durable and redosable treatments for conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs a proprietary platform that utilizes closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) to achieve targeted delivery of genetic materials across various tissues. This approach is designed to enhance treatment efficacy while expanding access to therapies for rare diseases and addressing more common conditions through scalable manufacturing processes.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

ADVANCE.AI is a data-driven financial technology company operating in the APAC region, focused on transforming the credit system through innovative scoring methods. The company aims to create a more holistic and accurate alternative to traditional credit assessments, promoting a more democratic approach to credit evaluation. ADVANCE.AI develops a big-data platform that offers anti-fraud detection services, facilitating loan applications with features such as multi-platform detection, face recognition, identity verification, company assessments, and credit score analytics. This comprehensive suite of services enables businesses to reduce manual verification costs and enhance operational efficiency. The company's leadership comprises experienced entrepreneurs and investors from prestigious institutions and backgrounds, bringing expertise from significant financial and technological firms.

Full Truck Alliance is a Chinese company that operates a platform connecting shippers with truckers to facilitate the transportation of goods over various distances and cargo weights. The company provides comprehensive services to both shippers and truckers through its mobile and web platforms. Its primary source of revenue comes from the use of these platforms for freight matching services, as well as additional value-added services. By streamlining the logistics process, Full Truck Alliance aims to enhance efficiency in freight transportation within the region.

Meituan Bike, previously known as Mobike, is a Chinese bicycle-sharing service that operates a fully station-less model. Founded in January 2015 by Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping, the company is headquartered in Beijing. Meituan Bike allows users to easily locate and rent bicycles through a mobile application, facilitating convenient transportation for short urban trips. The bicycles are equipped with smart locks and can be reserved via the app, offering a seamless user experience. In April 2018, the company was acquired by Meituan-Dianping for $2.7 billion and was rebranded as Meituan Bike in January 2019 as part of the integration process. The service has grown significantly since its inception, contributing to the development of urban mobility solutions in China.

Sea is a consumer internet company focused on enhancing the lives of consumers and small businesses in Southeast Asia through technology. Its primary businesses include Shopee, Garena, and SeaMoney. Shopee, the largest e-commerce platform in the region by gross merchandise value and transaction volume, operates as a hybrid C2C and B2C marketplace across eight key markets, with Indonesia being the largest contributor. Originally founded as a gaming company, Garena has evolved significantly, with its game Free Fire becoming the most downloaded game in early 2022 and a major revenue driver. SeaMoney complements these ventures by offering financial services, including lending, which is expected to grow in significance within the company’s portfolio. Through these diverse business lines, Sea aims to capitalize on the burgeoning digital economy in Southeast Asia.

The renewable energy arm of Hindustan Power Projects Pvt. Ltd .

PT Aplikasi Karya Anak Bangsa, commonly known as Gojek, is a mobile application-based platform founded in 2010 and headquartered in Jakarta, Indonesia. The company initially operated a motorcycle taxi fleet but has since evolved into a comprehensive Super App, offering a wide range of services including food delivery, transportation, digital payments, shopping, and various on-demand services such as massages. Launched in 2015, Gojek has rapidly become the largest consumer transactional technology group in Southeast Asia, driven by its commitment to speed, innovation, and social impact. The platform aims to empower the informal sector in the region while catering to diverse markets, including logistics, food, and entertainment.

Nexvet Australia Pty Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of biological therapies for companion animals. Founded in 2010, Nexvet focuses on creating species-specific monoclonal antibodies to address chronic pain, immune oncology, chronic inflammation, and allergies in pets. The company's key products include Ranevetmab and Frunevetmab, which target nerve growth factor to alleviate pain associated with osteoarthritis in dogs and degenerative joint disease in cats, respectively. Additionally, Nexvet is developing NV-03, a monoclonal antibody for chronic joint pain in horses. Utilizing a unique technology called PETisation, Nexvet customizes therapies to specific species, enhancing the effectiveness and safety of treatments while minimizing immune responses. As a subsidiary of Zoetis Inc., Nexvet aims to transform animal medicine by collaborating with global partners in veterinary and human health to advance its innovative pipeline.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

Sohu.com Ltd is a prominent Chinese online media and technology company that offers a diverse range of products and services across various platforms. Established in 1995, Sohu operates several key websites, including its main portal Sohu.com, the interactive search engine Sogou.com, and the gaming information site 17173.com. It is also involved in the real estate sector through focus.cn and provides online gaming through its subsidiary Changyou.com, which features popular titles like Tian Long Ba Bu, DDTank, and Wartune. In addition to its online gaming ventures, Sohu delivers news and information services via mobile applications such as the Sohu News app and WAP.Sohu.com. The company generates revenue primarily through online brand advertising and is dedicated to serving millions of users with its community-based, web 2.0 products on both PCs and mobile devices.

AdsIt is an online video advertisement provider based in Beijing, China.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

Beijing Adsit Media Technology Co., Ltd. is a leading distribution platform for internet-based video advertisements in China. As the operating company and technology service provider for Baidu's TV business model, it holds a unique position as the sole strategic brand management partner for Baidu. The company specializes in offering a range of online video advertising services, including floating, embedded, and streaming video advertisements. These services are designed to help businesses attract customers and enhance revenue, leveraging Adsit Media's innovative technology and customized solutions tailored for advertising agencies.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

E-House is a real estate services company in China offering a comprehensive online-to-offline (O2O) service platform. It offers primary sales agency services, online real estate services, real estate information and consulting services, real estate advertising services, real estate promotional event services, secondary real estate brokerage services, and real estate investment fund management services. E-House has served more than 80% of domestic real estate developers, including Vanke, Evergrande, Wanda, Longfor, Poly Real Estate, and many other real estate industry giants, and worked on more than 200,000 real estate projects. E-House was founded in 2004 and was first listed on the New York Stock Exchange in August 2007.

Heidi Coast Advertising Co., Ltd. is a Chinese company focused on the development and operation of campus media integrated marketing solutions. Heidi Coast Advertising’s leading brand, “China Campus Media,” covers new media such as campus video, campus outdoor, campus activity, CC176.com, and more. By cooperating with educational institutions and major domestic media organizations, the company spreads news, entertainment, programs, and advertisement information in universities and colleges, with students as the main audience group. It covers 18 economically developed cities and over 330 colleges and universities in China. It influences over 5 million people daily and maintains a campus broadcasting network.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.